Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy | Breast Cancer | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Mauri  D, Pavlidis  N, Ioannidis  JP.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.  J Natl Cancer Inst. 2005;97(3):188-194.PubMedGoogle ScholarCrossref
2.
Fisher  B, Bryant  J, Wolmark  N,  et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.  J Clin Oncol. 1998;16(8):2672-2685.PubMedGoogle Scholar
3.
Kuerer  HM, Newman  LA, Smith  TL,  et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.  J Clin Oncol. 1999;17(2):460-469.PubMedGoogle Scholar
4.
Hennessy  BT, Hortobagyi  GN, Rouzier  R,  et al.  Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.  J Clin Oncol. 2005;23(36):9304-9311.PubMedGoogle ScholarCrossref
5.
Bayraktar  S, Gonzalez-Angulo  AM, Lei  X,  et al.  Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.  Cancer. 2012;118(9):2385-2393.PubMedGoogle ScholarCrossref
6.
Untch  M, Fasching  PA, Konecny  GE,  et al.  Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.  J Clin Oncol. 2011;29(25):3351-3357.PubMedGoogle ScholarCrossref
7.
Dominici  LS, Negron Gonzalez  VM, Buzdar  AU,  et al.  Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.  Cancer. 2010;116(12):2884-2889.PubMedGoogle ScholarCrossref
8.
Rouzier  R, Extra  JM, Klijanienko  J,  et al.  Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.  J Clin Oncol. 2002;20(5):1304-1310.PubMedGoogle ScholarCrossref
9.
von Minckwitz  G, Untch  M, Blohmer  JU,  et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.  J Clin Oncol. 2012;30(15):1796-1804.PubMedGoogle ScholarCrossref
10.
McCready  DR, Hortobagyi  GN, Kau  SW, Smith  TL, Buzdar  AU, Balch  CM.  The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer.  Arch Surg. 1989;124(1):21-25.PubMedGoogle ScholarCrossref
11.
Schwartz  GF, Birchansky  CA, Komarnicky  LT,  et al.  Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast.  Cancer. 1994;73(2):362-369.PubMedGoogle ScholarCrossref
12.
Boughey  JC, Suman  VJ, Mittendorf  EA,  et al; Alliance for Clinical Trials in Oncology.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.  JAMA. 2013;310(14):1455-1461.Google ScholarCrossref
13.
Buzdar  A, Suman  VJ, Meric-Bernstam  F,  et al.  ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer.  J Clin Oncol.2013;31(suppl):abstract 502.Google Scholar
14.
Ohzawa  H, Sakatani  T, Niki  T, Yasuda  Y, Hozumi  Y.  Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.  Breast Cancer. 2014;21(5):563-570.PubMedGoogle ScholarCrossref
15.
Kaufmann  M, von Minckwitz  G, Mamounas  EP,  et al.  Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.  Ann Surg Oncol. 2012;19(5):1508-1516.PubMedGoogle ScholarCrossref
16.
Buzdar  AU, Valero  V, Ibrahim  NK,  et al.  Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.  Clin Cancer Res. 2007;13(1):228-233.PubMedGoogle ScholarCrossref
17.
Gianni  L, Eiermann  W, Semiglazov  V,  et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.  Lancet. 2010;375(9712):377-384.PubMedGoogle ScholarCrossref
18.
Baselga  J, Bradbury  I, Eidtmann  H,  et al; NeoALTTO Study Team.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [published correction appears in Lancet. 2012;379(9816):616].  Lancet. 2012;379(9816):633-640.PubMedGoogle ScholarCrossref
19.
Gianni  L, Pienkowski  T, Im  YH,  et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.  Lancet Oncol. 2012;13(1):25-32.PubMedGoogle ScholarCrossref
Original Investigation
April 2016

Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy

Author Affiliations
  • 1Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston
  • 2Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston
  • 3Center for Cancer and Blood Disorders, Arlington, Texas
  • 4Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston
  • 5Department of Pathology, University of Texas MD Anderson Cancer Center, Houston
  • 6Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston
  • 7Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston
  • 8Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston
JAMA Oncol. 2016;2(4):508-516. doi:10.1001/jamaoncol.2015.4935
Abstract

Importance  The long-term effect of axillary pathologic complete response (pCR) on survival among women with breast cancer treated with primary systemic chemotherapy (PST) is unknown.

Objective  To assess the long-term effect of axillary pCR on relapse-free survival (RFS) and overall survival (OS) in women with breast cancer with cytologically confirmed axillary lymph node metastases treated with PST.

Design, Setting, and Participants  We retrospectively analyzed the effect of axillary pCR on 10-year OS and RFS among all women who received a diagnosis of breast cancer stages II to III with cytologically confirmed axillary metastases between 1989 and 2007 who received PST at a large US comprehensive cancer center. Women were stratified by post-PST axillary status, and survival outcomes were estimated and compared according to response in the breast and axilla.

Main Outcomes and Measures  Outcomes of interest were RFS and OS.

Results  Of 1600 women treated, median (range) age at diagnisis was 49 (21-86) years. A total of 454 (28.4%) achieved axillary pCR. These patients were more likely to have human epidermal growth factor receptor 2 (HER2)-positive and triple-negative disease (P < .001), pCR in the breast (P < .001), high-grade tumors (P < .001), and lower clinical and pathologic T stage (P = .002). Ten-year OS rates were 84% (95% CI, 79%-88%) and 57% (95% CI, 54%-61%) (P < .001) and 10-year RFS rates 79% (95% CI, 74%-83%) and 50% (95% CI, 46%-53%) (P < .001) for patients with axillary pCR and residual axillary disease, respectively. For patients with axillary pCR, 10-year OS rates were 90% (95% CI, 84%-94%) for those with breast pCR and 72% (95% CI, 61%-80%) for those with residual breast disease (P < .001). For patients with residual axillary disease, 10-year OS rates were 66% (95% CI, 56%-74%) for patients with and 56% (95% CI, 52%-60%) for patients without breast pCR (P = .02). Of patients receiving HER2-targeted therapy for HER2-positive disease, 67.1% (100 of 149) achieved axillary pCR; 10-year OS rates were 92% (95% CI, 84%-96%) and 57% (95% CI, 20%-82%) (P = .003) and 10-year RFS rates 89% (95% CI, 81%-94%) and 44% (95% CI, 18%-68%) (P < .001) for those with axillary pCR and residual axillary disease, respectively.

Conclusions and Relevance  Axillary pCR was associated with improved 10-year OS and RFS. Patients with axillary and breast pCR after PST had superior long-term survival outcomes. Patients undergoing HER2-targeted therapy for HER2-positive disease had high rates of axillary pCR, and those with axillary pCR had excellent 10-year OS.

×